Neoplastic Process
Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal
Trodelvy, Triple Negative Breast Neoplasms, Metastatic to, Keytruda, Overall Survival
UK approval brings GSK’s Blenrep back from the brink
UK, Approved, Multiple Myeloma, DREAMM-8, dexamethasone, Blenrep, Antibody-Drug Conjugates, Risk, Cessation of life
J&J brushes off tariff headwinds with raised forecast, oncology surge
J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions
Illumina and Tempus look beyond cancer in new AI-driven genomics deal
Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market
Tempest Seeks Strategic Partners to Launch Phase 3 Liver Cancer Trial Amid Funding Challenges
Tempest Therapeutics , Amezalpat , Phase 3 Trial , Liver Cancer (HCC) , Strategic Partnerships , Biotech Funding , PPAR⍺ Antagonist , Clinical Oncology , FDA Clearance , Tecentriq and Avastin Combination Therapy
: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients
United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined
Lilly continues full-court press against breast cancer with women’s March Madness event sponsorships
Eli Lilly, Woman, Madness, Malignant neoplasm of breast, Event, Awareness, Basketball game
Corcept planning US, EU submissions for cortisol modulator after ovarian cancer win
Corcept, 130-nm albumin-bound paclitaxel
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BNT327, BioNTech, month, BioNTech ‘s, Small cell carcinoma of lung, Pharmacotherapy
BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody
Staff, Partner in relationship, CAB, BioAtla, 30%